Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
09/2002
09/05/2002US20020123493 For therapy and prophylaxis of neuronal damage
09/05/2002US20020123486 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
09/05/2002US20020123481 C-fos induced growth factor (FIGF) and DNA encoding same
09/05/2002US20020123477 Contacting a target cell with DNA-damaging agent; removing DNA-damaging agent from target cell; transferring transgene into target cell between about 1-3 days after removing DNA-damaging agent
09/05/2002US20020123476 For treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences
09/05/2002US20020123475 32626, a novel human UDP-glycosyltransferase and uses thereof
09/05/2002US20020123474 Human GTP-Rho binding protein2
09/05/2002US20020123473 For therapy of asthma
09/05/2002US20020123472 Exposing mammal to major histocompatibility complex class I and peptide, prior to, after, or concurrently with treating mammal to kill or inactivate autoimmune cells of mammal for increasing or maintaining number of functional cells
09/05/2002US20020123468 Alpha-ketoamide inhibitors of hepatitis C virus NS3 protease
09/05/2002US20020123467 For therapy of disease of central or peripheral nervous system
09/05/2002US20020123466 GLP-1 formulations
09/05/2002US20020123465 Administering transforming growth factor alpha (TGF- alpha ) polypeptide, fragments and mimetics to tissue or organ prior to, simultaneously with or subsequent to contacting the tissue or organ with the cytotoxic agent
09/05/2002US20020123464 Used for assessing whether test compound is useful for modulating phenomenon selected from group consisting of cell signaling, cell growth, cell differentiation, tumorigenesis, tumor growth, tumor metastasis, cell motility, etc.
09/05/2002US20020123463 As diagnostics, biosensors and bioreactors, pharmaceuticals
09/05/2002US20020123462 Modified ciliary neurotrophic factor, method of making and methods of use thereof
09/05/2002US20020123461 Enhancement of GLP-2 activity
09/05/2002US20020123460 Compositions for stabilizing oxygen-labile species
09/05/2002US20020123459 Pharmaceutical compositions for the oral delivery of pharmacologically active agents
09/05/2002US20020123458 Endostatin protein and fragments thereof
09/05/2002US20020123457 Novel antiplatelet agent
09/05/2002US20020123139 Antibodies which bind specifically to activin receptor like kinases
09/05/2002US20020123138 Human VNO receptor (R1)
09/05/2002US20020123122 Human DNase
09/05/2002US20020123121 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/05/2002US20020123120 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
09/05/2002US20020123119 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides and for treatment and prevention of infections
09/05/2002US20020123117 Modulator for use in the diagnosis and treatment of rheumatic diseases, cachexia and eating disorders
09/05/2002US20020123116 Suppressor protein for use in diagnosis, detection and treatment of cell proliferation and apoptosis defects
09/05/2002US20020123107 Nucleotide sequences coding transport protein for use in the diagnosis and treatment of atherosclerosis and nervous system disorders
09/05/2002US20020123106 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of nervous system disorders
09/05/2002US20020123105 Nucleotide sequences coing lantibiotic for use in the treatment and prevention of infections
09/05/2002US20020123104 Human slit polypeptide and polynucleotides encoding same
09/05/2002US20020123103 Polypeptide for use in the diagnosis and treatment of genetic disorders
09/05/2002US20020123102 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of thyroid defcets
09/05/2002US20020123099 Highly expressible genes
09/05/2002US20020123096 Dopamine receptors and genes
09/05/2002US20020123093 Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
09/05/2002US20020123091 Composition for use in the diagnosis, prevention and treatment of cardiovascular, endothelial or angiogenic disorders in mammals
09/05/2002US20020123083 Nucleic acid endocing growth factor protein
09/05/2002US20020123067 Chlamydia antigens and corresponding DNA fragments and uses thereof
09/05/2002US20020123047 dexB
09/05/2002US20020123044 Diagnosing cancer in humans; obtain biopsy of human tissue, detect and measure signal from bound polypeptide marker, evaluate humans for cancer
09/05/2002US20020123032 Detection of disease related genes
09/05/2002US20020122862 Dietetic food composition and dietetic method using such composition
09/05/2002US20020122829 Therapeutic agent for treatment of diabetes
09/05/2002US20020122827 Atomizing liquid solutions of the macromolecules, drying the droplets, and collecting the particles; process control; especially for proteins, a nucleic acids, and a high molecular weight polysaccharides.
09/05/2002US20020122816 Crosslinking an amine-containing biomolecule including chitosan, hemoglobin and a connective- tissue protein such as collagen or gelatin derived from a collagenous source
09/05/2002US20020122807 Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
09/05/2002US20020122806 Compositions and methods for in situ and in vivo imaging of cells and tissues
09/05/2002US20020122804 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host
09/05/2002US20020122802 Diagnosis and treatment of malignant neoplasms
09/05/2002US20020122801 Integrin-linked kinase and its uses
09/05/2002US20020122799 Administering soluble receptor for advanced glycation endproduct (RAGE) in an amount effective to inhibit binding of advanced glycation endproducts to RAGE
09/05/2002US20020122797 Monoclonal antibodies; hybridoma cell lines that produce such monoclonal antibodies.
09/05/2002US20020122796 Method for Inhibiting reperfusion injury using antibodies to P-selectin glycoprotein ligand
09/05/2002US20020122794 Antigenic preparation for treatment or prevention of helicobacter infection
09/05/2002US20020122793 Heparinase III and uses thereof
09/05/2002US20020122792 Induction of neoangiogenesis in ischemic myocardium
09/05/2002US20020122791 Antigenic CK-18 compounds for therapy and diagnosis and methods for using same
09/05/2002US20020122788 Long-term expression of gene products by transforming muscle cells
09/05/2002US20020122787 Cyanoacrylate polymer sealant and silver or a silver compound, the silver incorporated within the cyanoacrylate; especially for treatment of wounds in diabetics, normal patients and surgical patients.
09/05/2002US20020122774 Method for dispensing S-Adenosyl-methionine in a micro fine powdered form by inhalation
09/05/2002DE10111161A1 Neue Siderophoranaloga als 4- oder 6-zähnige Eisenchelatoren auf der Basis von Aminosäuren oder Peptiden, Verfahren zu ihrer Herstellung und ihre Anwendung New Siderophoranaloga as 4- or 6-dentate iron chelators based on amino acids or peptides, process for their preparation and their use
09/05/2002DE10109898A1 Lipide mit veränderlicher Ladung Lipids with variable charge
09/05/2002DE10109155A1 Verwendung von BK-RiV-Präparaten oder ihrer Einzelbestandteile zum Schutze der gesunden Leber, zur Therapie von Lebererkrankungen und zur Leberrekonstruktion nach Leberdestruktion beim Menschen und bei Tieren Use of BK-RiV preparations or its individual components for the Protection of healthy liver, for the treatment of liver diseases and liver reconstruction after liver destruction in humans and in animals
09/05/2002DE10107737A1 Verwendung eines Konjugats aus IL-6 und einem IL-6 Rezeptor zur Tumortherapie Use of a conjugate of IL-6 and an IL-6 receptor for tumor therapy
09/05/2002DE10107731A1 Verwendung eines polyfunktionellen Wirkstoffgemisches als Tabakrauchschadstoffantagonist als gesundheitsschützendes Mittel beim Tabakrauchen Using a polyfunctional active ingredient mixture as tobacco smoke pollution antagonist with a health protective agent in tobacco smoking
09/05/2002DE10106852A1 Entzündungshemmende Verbindungen Anti-inflammatory compounds
09/05/2002DE10106835A1 Signaltransduktionsproteine 15B3, 15B3-1 und 15B3-2 und zugrundeliegende DNA-Sequenzen Signal transduction 15B3, 15B3-1 and 15B3-2 and underlying DNA sequences
09/05/2002DE10106827A1 Verwendung eines Konjugats aus Interleukin-6(IL-6) und seinem Rezeptor zur Induktion der zellulären Expression des Stammzellfaktors (SCF) und von Flat-3-Ligand (Flt-3L) Use of a conjugate of interleukin-6 (IL-6) and its receptor in the induction of cellular expression of the stem cell factor (SCF) and Flat-3 ligand (Flt-3L)
09/05/2002DE10106718A1 Hefestamm von Saccharomyces cerevisiae mit funktioneller Expression eines Glut-Transporters Yeast strain of Saccharomyces cerevisiae with functional expression of Glut-transporter
09/05/2002CA2374147A1 Anti-wrinkle composition containing a derivative of polyaminoacid, and use of the said composition to combat wrinkling of the skin
09/04/2002EP1236800A2 Nucleic acids encoding interferon alpha 2, containing single nucleotide polymorphisms and methods of use thereof
09/04/2002EP1236799A2 Human nucleic acid sequences derived from breast tumor tissue
09/04/2002EP1236477A2 A formative agent of protein complex
09/04/2002EP1236475A2 Combination therapy for osteoporosis consisting of an estrogen agonist/antagonist and a growth hormone secretagogue
09/04/2002EP1236474A1 Negative regulation of epidermal growth factor receptor activity by Mig-6
09/04/2002EP1236473A2 Self-assembling polynucleotide delivery system
09/04/2002EP1235936A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
09/04/2002EP1235934A2 Screening method for candidate drugs
09/04/2002EP1235933A2 Mammalian toxicological response markers
09/04/2002EP1235924A1 Antisense modulation of rank expression
09/04/2002EP1235922A2 Excipient system that contains coating substances with enzymatically removable side-groups
09/04/2002EP1235914A2 Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
09/04/2002EP1235912A2 Tumour-specific vector for gene therapy
09/04/2002EP1235908A2 Polypeptides and polynucleotides encoding same
09/04/2002EP1235907A1 6 human secreted proteins
09/04/2002EP1235862A2 A major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralization antibodies
09/04/2002EP1235861A2 Novel steroid-activated nuclear receptors and uses therefor
09/04/2002EP1235860A2 G-protein coupled receptors
09/04/2002EP1235859A1 New olfactory receptor polypeptides and dna sequences thereof
09/04/2002EP1235858A1 Use of the insulin-like-growth factor i isoform mgf for the treatment of neurological disorders
09/04/2002EP1235846A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies
09/04/2002EP1235845A2 24 human secreted proteins
09/04/2002EP1235844A1 28 human secreted proteins
09/04/2002EP1235843A1 26 human secreted proteins
09/04/2002EP1235842A1 Rna interference pathway genes as tools for targeted genetic interference
09/04/2002EP1235838A1 23 human secreted proteins
09/04/2002EP1235837A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies